Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes

Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing